GLP-1 analogue-induced weight loss does not improve obesity-induced AT dysfunction

Clinical Science

Volumn 131, Issue 5, 2017, Pages 343-353

  Pastel, Emilie ^a   McCulloch, Laura J ^a   Ward, Rebecca ^a   Joshi, Shivam ^a   Gooding, Kim M ^a   Shore, Angela C ^a   Kos, Katarina ^a  

^a UNIVERSITY OF EXETER MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD14 ANTIGEN; COLLAGEN TYPE 1; COLLAGEN TYPE 1 ALPHA 1 CHAIN; GLICLAZIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LIRAGLUTIDE; METFORMIN; MONOCYTE CHEMOTACTIC PROTEIN 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; ADIPONECTIN; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1; LEPTIN;

ADIPOSE TISSUE BIOPSY; ADIPOSE TISSUE DYSFUNCTION; ADULT; ARTICLE; BIOPSY; BODY MASS; CALORIC RESTRICTION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; EXTRACELLULAR MATRIX; FAT MASS; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INTRAPERITONEAL FAT; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITIONAL COUNSELING; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS FAT DISORDER; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE; WAIST HIP RATIO; WEIGHT REDUCTION; ADIPOSE TISSUE; AGED; ANALOGS AND DERIVATIVES; COMPLICATION; DRUG EFFECTS; INFLAMMATION; METABOLISM; MIDDLE AGED;

ADIPONECTIN; ADIPOSE TISSUE; AGED; DIABETES MELLITUS, TYPE 2; EXTRACELLULAR MATRIX; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INFLAMMATION; LEPTIN; LIRAGLUTIDE; MALE; MIDDLE AGED; OBESITY;

EID: 85015079698     PISSN: 01435221     EISSN: 14708736     Source Type: Journal    
DOI: 10.1042/CS20160803     Document Type: Article

References (46)

1. Holst, J.J. (2007) The physiology of glucagon-like peptide 1. Physiol. Rev. 87, 1409-1439
2. Vilsboll, T., Christensen, M., Junker, A.E., Knop, F.K. and Gluud, L.L. (2012) Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. Br. Med. J. 344, d7771
3. Cuthbertson, D.J., Irwin, A., Gardner, C.J., Daousi, C., Purewal, T., Furlong, N. et al. (2012) Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists. PLoS One 7, 8-11
4. Vendrell, J., El Bekay, R., Peral, B., Garćia-Fuentes, E., Megia, A., Macias-Gonzalez, M. et al. (2011) Study of the potential association of adipose tissue GLP-1 receptor with obesity and insulin resistance. Endocrinology 152, 4072-4079
5. Pastel, E., Joshi, S., Knight, B., Liversedge, N., Ward, R. and Kos, K. (2016) Effects of exendin-4 on human adipose tissue inflammation and ECM remodelling. Nutr. Diabetes 6, e235
6. Cantini, G., Di Franco, A., Samavat, J., Forti, G., Mannucci, E. and Luconi, M. (2015) Effect of liraglutide on proliferation and differentiation of human adipose stem cells. Mol. Cell. Endocrinol. 402, 43-50
7. Laforest, S., Labrecque, J., Michaud, A., Cianflone, K. and Tchernof, A. (2015) Adipocyte size as a determinant of metabolic disease and adipose tissue dysfunction. Crit. Rev. Clin. Lab. Sci. 52, 301-313
8. Sun, K., Tordjman, J., Clément, K. and Scherer, P.E. (2013) Fibrosis and adipose tissue dysfunction. Cell Metab. 18, 470-477
9. Heilbronn, L., Smith, S.R. and Ravussin, E. (2004) Failure of fat cell proliferation, mitochondrial function and fat oxidation results in ectopic fat storage, insulin resistance and type II diabetes mellitus. Int. J. Obes. Relat. Metab. Disord. 28 Suppl 4, S12-S21
10. Virtue, S. and Vidal-Puig, A. (2010) Adipose tissue expandability, lipotoxicity and the metabolic syndrome-an allostatic perspective. Biochim. Biophys. Acta-Mol. Cell Biol. Lipids 1801, 338-349
11. Rossmeislová, L., Mališová, L., Kračmerová, J., Tencerová, M., Kováčová, Z., Koc, M. et al. (2013) Weight loss improves the adipogenic capacity of human preadipocytes and modulates their secretory profile. Diabetes 62, 1990-1995
12. Clément, K., Viguerie, N., Poitou, C., Carette, C., Pelloux, V., Curat, C.A. et al. (2004) Weight loss regulates inflammation-related genes in white adipose tissue of obese subjects. FASEB J. 18, 1657-1669
13. Cancello, R., Henegar, C., Viguerie, N., Taleb, S., Poitou, C., Rouault, C. et al. (2005) Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss. Diabetes 54, 2277-2286
14. Arvidsson, E., Viguerie, N., Andersson, I., Verdich, C., Langin, D. and Arner, P. (2004) Effects of different hypocaloric diets on protein secretion from adipose tissue of obese women. Diabetes 53, 1966-1971
15. Divoux, A., Tordjman, J., Lacasa, D., Veyrie, N., Hugol, D., Aissat, A. et al. (2010) Fibrosis in human adipose tissue: composition, distribution, and link with lipid metabolism and fat. Diabetes 59, 2817-2825
16. Baggio, L.L. and Drucker, D.J. (2014) Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight. J. Clin. Invest. 124, 4223-4226
17. McCulloch, L.J., Rawling, T.J., Sjöholm, K., Franck, N., Dankel, S.N., Price, E.J. et al. (2015) COL6A3 is regulated by leptin in human adipose tissue and reduced in obesity. Endocrinology 156, 134-146
18. Gastaldelli, A., Harrison, S.A., Belfort-Aguilar, R., Hardies, L.J., Balas, B., Schenker, S. et al. (2009) Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis. Hepatology 50, 1087-1093
19. Ouchi, N., Kihara, S., Funahashi, T., Nakamura, T., Nishida, M., Kumada, M. et al. (2003) Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 107, 671-674
20. Kershaw, E.E. and Flier, J.S. (2004) Adipose tissue as an endocrine organ. J. Clin. Endocrinol. Metab. 89, 2548-2556
21. Dalmas, E., Clément, K. and Guerre-Millo, M. (2011) Defining macrophage phenotype and function in adipose tissue. Trends Immunol. 32, 307-314
22. Alkhouli, N., Mansfield, J., Green, E., Bell, J., Knight, B., Liversedge, N. et al. (2013) The mechanical properties of human adipose tissues and their relationships to the structure and composition of the extracellular matrix. Am. J. Physiol. Endocrinol. Metab. 305, E1427-E1435
23. Trayhurn, P., Wang, B. and Wood, I.S. (2008) Hypoxia in adipose tissue: a basis for the dysregulation of tissue function in obesity? Br. J. Nutr. 100, 227-235
24. Daousi, C., Pinkney, J.H., Cleator, J., Wilding, J.P. and Ranganath, L.R. (2013) Acute peripheral administration of synthetic human GLP-1 (7-36 amide) decreases circulating IL-6 in obese patients with type 2 diabetes mellitus: a potential role for GLP-1 in modulation of the diabetic pro-inflammatory state? Regul. Pept. 183, 54-61
25. Díaz-Soto, G., De Luis, D.A., Conde-Vicente, R., Izaola-Jauregui, O., Ramos, C. and Romero, E. (2014) Beneficial effects of liraglutide on adipocytokines, insulin sensitivity parameters and cardiovascular risk biomarkers in patients with Type 2 diabetes: a prospective study. Diabetes Res. Clin. Pract. 104, 92-96
26. El Bekay, R., Coín-Araguüez, L., Fernández-Garćia, D., Oliva-Olivera, W., Bernal-López, R., Clemente-Postigo, M. et al. (2016) Effects of GLP-1 on the differentiation and metabolism of human adipocytes. Br. J. Pharmacol. 173, 1820-1834
27. Pellegrinelli, V., Carobbio, S. and Vidal-Puig, A. (2016) Adipose tissue plasticity: how fat depots respond differently to pathophysiological cues. Diabetologia 59, 1075-1088
28. Vilsbøll, T., Zdravkovic, M., Le-Thi, T., Krarup, T., Schmitz, O., Courrèges, J. et al. (2007) Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with Type 2 diabetes. Diabetes Care 30, 1608-1610
29. Suzuki, D., Toyoda, M., Kimura, M., Miyauchi, M., Yamamoto, N., Sato, H. et al. (2013) Effects of liraglutide, a human glucagon-like peptide-1 analogue, on body weight, body fat area and body fat-related markers in patients with type 2 diabetes mellitus. Intern. Med. 52, 1029-1034
30. Irwin, N., Hunter, K., Frizzell, N. and Flatt, P.R. (2009) Antidiabetic effects of sub-chronic activation of the GIP receptor alone and in combination with background exendin-4 therapy in high fat fed mice. Regul. Pept. 153, 70-76
31. Klempel, M.C. and Varady, K.A. (2011) Reliability of leptin, but not adiponectin, as a biomarker for diet-induced weight loss in humans. Nutr. Rev. 69, 145-154
32. Tanaka, K., Masaki, Y., Tanaka, M., Miyazaki, M., Enjoji, M., Nakamuta, M. et al. (2014) Exenatide improves hepatic steatosis by enhancing lipid use in adipose tissue in nondiabetic rats. World J. Gastroenterol. 20, 2653-2663
33. Lee, Y.S., Park, M.S., Choung, J.S., Kim, S.S., Oh, H.H., Choi, C.S. et al. (2012) Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes. Diabetologia 55, 2456-2468
34. Zhou, Y., Yu, X., Chen, H., Sjöberg, S., Roux, J., Zhang, L. et al. (2015) Leptin deficiency shifts mast cells toward anti-inflammatory actions and protects mice from obesity and diabetes by polarizing M2 macrophages. Cell Metab. 22, 1045-1058
35. Bunck, M.C., Diamant, M., Eliasson, B., Cornér, A., Shaginian, R.M., Heine, R.J. et al. (2010) Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition. Diabetes Care 33, 1734-1737
36. Chaudhuri, A., Ghanim, H., Vora, M., Sia, C.L., Korzeniewski, K., Dhindsa, S. et al. (2012) Exenatide exerts a potent antiinflammatory effect. J. Clin. Endocrinol. Metab. 97, 198-207
37. Hogan, A.E., Gaoatswe, G., Lynch, L., Corrigan, M.A., Woods, C., O'Connell, J. et al. (2014) Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus. Diabetologia 57, 781-784
38. Bourlier, V., Sengenès, C., Zakaroff-Girard, A., Decaunes, P., Wdziekonski, B., Galitzky, J. et al. (2012) TGFbeta family members are key mediators in the induction of myofibroblast phenotype of human adipose tissue progenitor cells by macrophages. PLoS One 7, e31274
39. Liu, Y., Aron-Wisnewsky, J., Marcelin, G., Genser, L., Le Naour, G., Torcivia, A. et al. (2016) Accumulation and changes in composition of collagens in subcutaneous adipose tissue following bariatric surgery. J. Clin. Endocrinol. Metab. 101, 293-304
40. Armstrong, M.J., Gaunt, P., Aithal, G.P., Barton, D., Hull, D., Parker, R. et al. (2015) Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 1, 679-690
41. Robinson, E., Cassidy, R.S., Tate, M., Zhao, Y., Lockhart, S., Calderwood, D. et al. (2015) Exendin-4 protects against post-myocardial infarction remodelling via specific actions on inflammation and the extracellular matrix. Basic Res. Cardiol. 110, 20
42. Gao, H., Wang, X., Zhang, Z., Yang, Y., Yang, J., Li, X. et al. (2007) GLP-1 amplifies insulin signaling by up-regulation of IRβ, IRS-1 and Glut4 in 3T3-L1 adipocytes. Endocrine 32, 90-95
43. Yang, J., Ren, J., Song, J., Liu, F., Wu, C., Wang, X. et al. (2013) Glucagon-like peptide 1 regulates adipogenesis in 3T3-L1 preadipocytes. Int. J. Mol. Med. 31, 1429-1435
44. Liu, R., Li, N., Lin, Y., Wang, M., Peng, Y., Lewi, K. et al. (2016) Glucagon like peptide-1 promotes adipocyte differentiation via the Wnt4 mediated sequestering of beta-catenin. PLoS One 11, e0160212
45. Wernstedt, Asterholm, I., Tao, C., Morley, T.S., Wang, Q.A., Delgado-Lopez, F., Wang, Z V. et al. (2014) Adipocyte inflammation is essential for healthy adipose tissue expansion and remodeling. Cell Metab. 20, 103-118
46. Gustafson, B. and Smith, U. (2006) Cytokines promote Wnt signaling and inflammation and impair the normal differentiation and lipid accumulation in 3T3-L1 preadipocytes. J. Biol. Chem. 281, 9507-9516